WJD008

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561297

CAS#: 1309087-83-9

Description: WJD008 is a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor. WJD008 also prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. WJD008 has antiproliferative and anticlonogenic activity in tumor cells.


Price and Availability

Size
Price

Size
Price

Size
Price

WJD008 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561297
Name: WJD008
CAS#: 1309087-83-9
Chemical Formula: C19H21N5O2
Exact Mass: 351.1695
Molecular Weight: 351.41
Elemental Analysis: C, 64.94; H, 6.02; N, 19.93; O, 9.11


Synonym: WJD008; WJD 008; WJD-008

IUPAC/Chemical Name: 4-[2-(Dimethylamino)ethenyl]-2-(3-hydroxyphenyl)-6-(4-morpholinyl)-5-pyrimidinecarbonitrile

InChi Key: NOXRZMIVCROOPI-VOTSOKGWSA-N

InChi Code: InChI=1S/C19H21N5O2/c1-23(2)7-6-17-16(13-20)19(24-8-10-26-11-9-24)22-18(21-17)14-4-3-5-15(25)12-14/h3-7,12,25H,8-11H2,1-2H3/b7-6+

SMILES Code: N#CC1=C(N2CCOCC2)N=C(C3=CC=CC(O)=C3)N=C1/C=C/N(C)C


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Wang X, Li JP, Yang Y, Ding J, Meng LH. A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth. Acta Pharmacol Sin. 2013 Sep;34(9):1201-7. doi: 10.1038/aps.2013.81. Epub 2013 Jul 29. PubMed PMID: 23892273; PubMed Central PMCID: PMC4003165.

2: Zhou HY, Huang SL. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer. 2012 Jan;31(1):8-18. doi: 10.5732/cjc.011.10281. Epub 2011 Nov 4. Review. PubMed PMID: 22059905; PubMed Central PMCID: PMC3249493.

3: Schenone S, Brullo C, Musumeci F, Radi M, Botta M. ATP-competitive inhibitors of mTOR: an update. Curr Med Chem. 2011;18(20):2995-3014. Review. PubMed PMID: 21651476.

4: Li T, Wang J, Wang X, Yang N, Chen SM, Tong LJ, Yang CH, Meng LH, Ding J. WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. J Pharmacol Exp Ther. 2010 Sep 1;334(3):830-8. doi: 10.1124/jpet.110.167940. Epub 2010 Jun 3. PubMed PMID: 20522531.